Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CAR T-cell therapy for a relapsed/refractory acute B-cell lymphoblastic lymphoma patient in the context of Li-Fraumeni syndrome.

Journal for immunotherapy of cancer - 1 Apr 2020

Chen Liting, Xu Bin, Long Xiaolu, Gu Jia, Lou Yaoyao, Wang Di, Cao Yang, Wang Na, Li Chunrui, Wang Gaoxiang, Wang Ying, Zhu Li, Wang Jin, An Haiyun, Xiao Min, Xiao Yi, Zhou Jianfeng

Abstract excerpt

BACKGROUND: Li-Fraumeni syndrome (LFS) is characterized as an autosomal dominant cancer predisposition disorder caused by germline TP53 gene mutations. Both primary and therapy-related hematopoietic malignancies with LFS are associated with dismal outcomes with standard therapies and even allogenic stem cell transplantation (SCT). CASE PRESENTATION: We reported a relapsed/refractory acute B-cell lymphoblastic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Disease
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunotherapy, Adoptive

Share to Li-Fraumeni Syndrome

Share to Neoplasm Recurrence, Local

Share to Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

Share to Salvage Therapy

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 32345625
DOI: 10.1136/jitc-2019-000364
PMCID: PMC7213909

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CAR T-cell therapy for a relapsed/refractory acute B-cell lymphoblastic lymphoma patient in the context of Li-Fraumeni syndrome.PMID 32345625Read ↗

Case report: Sandwich therapy of CAR-T combined with ASCT: Sequential CAR-T cell therapy with ASCT after remission with CAR-T therapy caused long-term survival in a patient with relapsed/refractory Burkitt's lymphoma with TP53 mutations.Semantic proximity Read ↗

Hematologic malignancies in Li-Fraumeni syndrome: A case report.Semantic proximity Read ↗

Whether CAR-T cell bridging to allo-HSCT increases the incidence of graft-versus-host disease in patients with high-risk chronic lymphocytic leukemiaSemantic proximity Read ↗

[Li-Fraumeni syndrome in adult patients with acute lymphoblastic leukemia].Semantic proximity Read ↗

Treatment of Chronic Lymphocytic Leukemia With del(17p)/TP53 Mutation: Allogeneic Hematopoietic Stem Cell Transplantation or BCR-Signaling Inhibitors?Semantic proximity Read ↗

[Treatment of Chronic Lymphocytic Leukemia with TP53 Aberrations].Semantic proximity Read ↗

Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial.Semantic proximity Read ↗

Impact of TP53 mutations on survival outcomes in the CAR-T era of large B-cell lymphoma.Semantic proximity Read ↗

CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

Leukemic and non-leukemic lymphocytes from patients with Li Fraumeni syndrome demonstrate loss of p53 function, Bcl-2 family dysregulation and intrinsic resistance to conventional chemotherapeutic drugs but not flavopiridol.Semantic proximity Read ↗

Fatal Progression of Mutated TP53-Associated Clonal Hematopoiesis following Anti-CD19 CAR-T Cell Therapy.Semantic proximity Read ↗

A phase two study of high dose blinatumomab in Richter's syndrome.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.